Allogene Therapeutics is a clinical-stage biotechnology company with a single-minded focus on pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. These off-the-shelf therapies, enhanced by gene editing, could be the next vital breakthrough in the field of cancer treatment, making cell therapy faster, more reliable, and available at greater scale to more patients. In this video, leaders from Allogene and TPG reflect on our partnership and the groundbreaking work of the company.
INSIGHTS
See the world from a different vantage
We bring an innovator’s mindset to everything we do—shaping how we create differentiated opportunity and drive success in a changing world.


